Introduction: Regarding to the role of the zinc in the metabolism of the central nervous system and the correlation of zinc supplementation in the treatment of any Attention deficit hyperactivity disorder (ADHD) symptoms, this study was conducted to evaluate the complementary effects of this nutrient.
Method: This was a double-blind randomized clinical trial study and 60 children with ADHD who were treated with methylphenidate were chosen by random allocation and were divided in the two groups: 30 for the case and 30 for the control group. The treatment in case group was augmented with zinc. Duration of study was six weeks.
Result: Forty eight (80%) of participants were boy and 12 (20%) were girl. The mean age of patients was 9.6 ± 1.70 years. There was no significant difference between the two groups after the intervention in terms of total score, hyperactivity and impulsivity subscales during variance analysis, but there was a significant difference between the mean of inattention score.
Conclusion: Augmentation with zinc can enhance the improvement of inattention.
Keywords: Attention deficit hyperactivity disorder; Augmentation; Connors questionnaire; Methylphenidate; Zinc.
Copyright © 2019 Elsevier B.V. All rights reserved.
Zinc sulfate as an adjunct to methylphenidate for the treatment of attention deficit hyperactivity disorder in children: a double blind and randomized trial [ISRCTN64132371].BMC Psychiatry. 2004 Apr 8;4:9. doi: 10.1186/1471-244X-4-9. BMC Psychiatry. 2004. PMID: 15070418 Free PMC article. Clinical Trial.
Methylphenidate for children and adolescents with autism spectrum disorder.Cochrane Database Syst Rev. 2017 Nov 21;11(11):CD011144. doi: 10.1002/14651858.CD011144.pub2. Cochrane Database Syst Rev. 2017. PMID: 29159857 Free PMC article. Review.
Randomized clinical study of a histamine H3 receptor antagonist for the treatment of adults with attention-deficit hyperactivity disorder.CNS Drugs. 2012 May 1;26(5):421-34. doi: 10.2165/11631990-000000000-00000. CNS Drugs. 2012. PMID: 22519922 Clinical Trial.
Immediate-release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults.Cochrane Database Syst Rev. 2014 Sep 18;(9):CD005041. doi: 10.1002/14651858.CD005041.pub2. Cochrane Database Syst Rev. 2014. PMID: 25230710 Updated. Review.
Randomized, Double-Blind, Placebo-Controlled Acute Comparator Trials of Lisdexamfetamine and Extended-Release Methylphenidate in Adolescents With Attention-Deficit/Hyperactivity Disorder.CNS Drugs. 2017 Nov;31(11):999-1014. doi: 10.1007/s40263-017-0468-2. CNS Drugs. 2017. PMID: 28980198 Free PMC article.